^
CANCER:
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
CAV
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
cisplatin
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
carboplatin
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
carboplatin + etoposide IV
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
cisplatin + etoposide IV
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
carboplatin + gemcitabine
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
cisplatin + topotecan
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
cisplatin + irinotecan
Sensitive
:
A2
ESMO.org - 3wk
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
topotecan
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
lurbinectedin
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
nivolumab
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
docetaxel
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
temozolomide
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
etoposide oral
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
vinorelbine tartrate
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
gemcitabine
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
bendamustine
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
irinotecan
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
bevacizumab
Resistant
:
A2
No biomarker
Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
trilaciclib
Sensitive
:
B
No biomarker
Small Cell Lung Cancer
CS 2164
Sensitive
:
B
No biomarker
Small Cell Lung Cancer
nanoliposomal irinotecan
Sensitive
:
B
TMB-H
Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
B
TMB-H
Small Cell Lung Cancer
nivolumab
Sensitive
:
B
PD-L1 expression
Small Cell Lung Cancer
atezolizumab
Sensitive
:
C1
HER-2 positive
Small Cell Lung Cancer
trastuzumab
Sensitive
:
C1
NTRK3 fusion
Small Cell Lung Cancer
larotrectinib
Sensitive
:
C1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our